Immunogenicity of live attenuated hepatitis A vaccine in overweight and obese children/adolescent/young adult

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20191230001

Enrollment

200

Registered

2019-12-30

Start date

2019-11-25

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight or obesity Hepatitis A vaccine&#44

Interventions

Subjects with overweight or obesity. Vaccine used: MEVAC&#45

Aâ„¢ (H2 strain&#44

freeze dried&#44

live vaccine)&#44

Zhejiang Pukang Biotechnological Co&#44

Ltd&#44

Peopleâ€™s Republic of China ,Subjects with normal weight. Vaccine used:same

Experimental Biological/Vaccine,Experimental Biological/Vaccine

HAV vaccine,HAV vaccine

Eligibility

Sex/Gender

All

Age

6 Years to 25 Years

Inclusion criteria

Inclusion criteria: - Normal weight - Overweight or obese

Exclusion criteria

Exclusion criteria: - Persons who are immunized with hepatitis A vaccine - Persons with immunodeficiency - Person who receive immunosuppressive drugs

Design outcomes

Primary

Measure	Time frame
The immunogenicity of HAV vaccine 8 weeks post vaccination Serology	—

Secondary

Measure	Time frame
Factors associated with impaired immunogenicity to HAV vaccine Day of vaccination Body mass index, signs of insulin resistance	—

Countries

Thailand

Contacts

Public ContactVoranush Chongsrisawat

Department of Pediatrics, Faculty of Medicine, Chulalongkorn University

voranush.c@chula.ac.th022564951

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026